PMID- 36200065
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221007
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 15
DP  - 2022
TI  - Prevalence and Risk Factors of Osteoporosis in Patients with Type 2 Diabetes 
      Mellitus in Nanchang (China): A Retrospective Cohort Study.
PG  - 3039-3048
LID - 10.2147/DMSO.S372348 [doi]
AB  - OBJECTIVE: To retrospectively review the clinical data of type 2 diabetes 
      mellitus (T2DM) patients hospitalized in Nanchang, China, summarized the 
      prevalence of osteoporosis (OP) in T2DM patients in this area, and analyzed 
      related influencing factors. METHODS: The clinical data of hospitalized patients 
      with T2DM were collected retrospectively. According to the results of bone 
      mineral density test, the subjects were divided into the normal bone mass group, 
      the osteopenia group, and the OP group. Age, gender, educational background, body 
      mass index (BMI), waist-to-hip ratio (WHR), duration of T2DM, glycosylated 
      hemoglobin, serum lipids, and complications of T2DM in the three groups were 
      analyzed and compared. RESULTS: The prevalence of OP in patients with T2DM was 
      35.77%. There were statistically significant differences in age, gender, BMI, 
      WHR, duration of T2DM, educational background, the level of high-density 
      lipoprotein cholesterol (HDL-C), the prevalence of diabetic retinopathy (DR), and 
      diabetic peripheral neuropathy among the three groups (P < 0.05). Logistic 
      regression analysis showed that increasing age, prolonged duration of T2DM, low 
      BMI, high levels of HDL-C, and complicated DR were risk factors for osteopenia 
      and OP. CONCLUSION: The prevalence of OP in T2DM was high. Risk factors for 
      abnormal bone mass in T2DM might be females, advanced age, long duration of T2DM, 
      low BMI, high levels of HDL-C, and diabetic microangiopathy.
CI  - (c) 2022 Li et al.
FAU - Li, Ting
AU  - Li T
AD  - Department of Endocrinology, The First Hospital of Nanchang (The Third Affiliated 
      Hospital of Nanchang University), Nanchang, Jiangxi, People's Republic of China.
FAU - Hu, Ling
AU  - Hu L
AD  - Department of Endocrinology, The First Hospital of Nanchang (The Third Affiliated 
      Hospital of Nanchang University), Nanchang, Jiangxi, People's Republic of China.
FAU - Yin, Xiao-Ling
AU  - Yin XL
AD  - Department of Endocrinology, The First Hospital of Nanchang (The Third Affiliated 
      Hospital of Nanchang University), Nanchang, Jiangxi, People's Republic of China.
FAU - Zou, Yi
AU  - Zou Y
AD  - Department of Endocrinology, The First Hospital of Nanchang (The Third Affiliated 
      Hospital of Nanchang University), Nanchang, Jiangxi, People's Republic of China.
FAU - Fu, Hai-Yan
AU  - Fu HY
AD  - Department of Endocrinology, The First Hospital of Nanchang (The Third Affiliated 
      Hospital of Nanchang University), Nanchang, Jiangxi, People's Republic of China.
FAU - Li, Hong-Lin
AU  - Li HL
AD  - Department of Biochemistry, Medical College of Georgia, Augusta, GA, USA.
LA  - eng
PT  - Journal Article
DEP - 20220928
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC9527700
OTO - NOTNLM
OT  - osteoporosis
OT  - prevalence
OT  - risk-factors
OT  - type 2 diabetes mellitus
COIS- The authors declare that they have no competing interests in this work.
EDAT- 2022/10/07 06:00
MHDA- 2022/10/07 06:01
PMCR- 2022/09/28
CRDT- 2022/10/06 02:18
PHST- 2022/04/26 00:00 [received]
PHST- 2022/08/14 00:00 [accepted]
PHST- 2022/10/06 02:18 [entrez]
PHST- 2022/10/07 06:00 [pubmed]
PHST- 2022/10/07 06:01 [medline]
PHST- 2022/09/28 00:00 [pmc-release]
AID - 372348 [pii]
AID - 10.2147/DMSO.S372348 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2022 Sep 28;15:3039-3048. doi: 10.2147/DMSO.S372348. 
      eCollection 2022.